Cocrystal Receives FDA Fast Track Designation for CDI-988, Shares Surge
Cocrystal Pharma's shares skyrocketed nearly 58% after the company received FDA Fast Track designation for its promising drug CDI-988, aimed at treating norovirus. This designation can significantly accelerate regulatory processes, presenting a favorable outlook for both the drug's development and market potential.
View signal analysis